[A19-72] Ropeginterferon alfa-2b (polycythaemia vera) - Benefit assessment according to §35a Social Code Book V
Last updated 05.03.2020
Project no.:
A19-72
Commission:
Commission awarded on 28.08.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Polycythaemia vera in adults who do not have symptoms of an enlarged spleen
Added benefit not proven
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2019-12-16.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.